Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVDL

AVDL - Avadel Pharmaceuticals PLC Stock Price, Fair Value and News

12.60USD-0.08 (-0.63%)Market Closed
Watchlist

Market Summary

USD12.60-0.08
Market Closed
-0.63%

AVDL Alerts

  • JANUS HENDERSON GROUP PLC reported owning 12.4% of AVDL [2024-02-13]
  • 1 major insider buys recently.

AVDL Stock Price

View Fullscreen

AVDL RSI Chart

AVDL Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-7.12

Price/Sales (Trailing)

541.98

EV/EBITDA

-7.39

Price/Free Cashflow

-10.89

AVDL Price/Sales (Trailing)

AVDL Profitability

EBT Margin

-6797.10%

Return on Equity

-144.3%

Return on Assets

-78.26%

Free Cashflow Yield

-9.18%

AVDL Fundamentals

AVDL Revenue

Revenue (TTM)

2.3M

Rev. Growth (Yr)

1.5K%

Rev. Growth (Qtr)

368.85%

AVDL Earnings

Earnings (TTM)

-158.9M

Earnings Growth (Yr)

-80.06%

Earnings Growth (Qtr)

43.7%

Breaking Down AVDL Revenue

Last 7 days

-5.9%

Last 30 days

-8.3%

Last 90 days

25.7%

Trailing 12 Months

74.9%

How does AVDL drawdown profile look like?

AVDL Financial Health

Current Ratio

3.19

AVDL Investor Care

Shares Dilution (1Y)

45.37%

Diluted EPS (TTM)

-2.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
202117.3M12.3M7.3M2.3M
202055.0M47.6M33.3M22.3M
201986.4M74.7M69.1M59.2M
2018154.4M136.6M116.7M103.3M
2017166.2M175.1M182.7M173.6M
2016176.6M166.2M150.9M149.9M
201554.5M94.0M133.6M173.1M
20146.9M9.6M12.3M15.0M
20136.7M5.9M5.0M4.2M
201226.3M20.1M13.8M7.5M
201136.0M34.8M33.7M32.6M
201040.9M39.6M38.4M37.1M
200900042.1M

Tracking the Latest Insider Buys and Sells of Avadel Pharmaceuticals PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 16, 2024
mchugh thomas s
bought
29,000
14.5
2,000
chief financial officer
Dec 28, 2023
mccamish mark anthony
sold
-1,089,750
14.53
-75,000
-
Aug 14, 2023
mchugh thomas s
bought
28,900
14.45
2,000
chief financial officer
Aug 11, 2023
mccamish mark anthony
sold
-432,614
14.9306
-28,975
-
Aug 10, 2023
divis gregory j
bought
131,997
13.1997
10,000
chief executive officer
Aug 10, 2023
glass geoffrey michael
bought
187,600
13.4
14,000
-
May 18, 2023
ende eric j
bought
181,100
13.9308
13,000
-
May 09, 2023
palczuk linda
bought
36,900
14.76
2,500
-
Dec 23, 2022
palczuk linda
bought
14,405
7.2025
2,000
-
Nov 29, 2022
mchugh thomas s
bought
39,000
7.8
5,000
chief financial officer

1–10 of 46

Which funds bought or sold AVDL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
new
-
120,020
120,020
0.02%
Feb 20, 2024
Able Wealth Management LLC
new
-
1,624
1,624
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-50.00
-
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
406
1,328,550
1,551,860
-%
Feb 15, 2024
GTS SECURITIES LLC
added
267
714,833
891,622
-%
Feb 15, 2024
State of Wyoming
added
16.51
257,150
687,700
0.13%
Feb 14, 2024
Checkpoint Capital L.P.
new
-
4,589,000
4,589,000
2.78%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
unchanged
-
284,972
1,053,350
-%
Feb 14, 2024
Royal Bank of Canada
unchanged
-
13,000
50,000
-%
Feb 14, 2024
GENDELL JEFFREY L
unchanged
-
21,450,600
79,288,700
4.31%

1–10 of 40

Are Funds Buying or Selling AVDL?

Are funds buying AVDL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVDL
No. of Funds

Unveiling Avadel Pharmaceuticals PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
rtw investments, lp
9.99%
9,196,186
SC 13G/A
Feb 13, 2024
polar capital holdings plc
7.51%
6,751,782
SC 13G
Feb 13, 2024
janus henderson group plc
12.4%
11,125,330
SC 13G/A
Feb 13, 2024
gendell jeffrey l
3.94%
3,539,782
SC 13G/A
Feb 12, 2024
kotler kevin
4.1%
3,716,242
SC 13G/A
Aug 10, 2023
janus henderson group plc
12.3%
9,443,642
SC 13G
Mar 09, 2023
kotler kevin
5.1%
3,122,100
SC 13G
Feb 14, 2023
gendell jeffrey l
5.33%
3,294,817
SC 13G/A
Feb 14, 2023
rtw investments, lp
9.3%
5,741,939
SC 13G/A
Feb 14, 2023
vivo opportunity, llc
3.6%
2,251,663
SC 13G/A

Recent SEC filings of Avadel Pharmaceuticals PLC

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G
Major Ownership Report
Feb 12, 2024
SC 13G/A
Major Ownership Report
Jan 16, 2024
4
Insider Trading
Jan 08, 2024
8-K
Current Report
Dec 29, 2023
4
Insider Trading
Dec 28, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Avadel Pharmaceuticals PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
386.5B
93.0B
-3.60% -2.76%
10.99
4.15
6.46% 95.94%
156.0B
46.5B
-3.76% -37.06%
-112.32
3.35
42.59% -114.62%
152.8B
28.2B
-7.44% 18.02%
22.75
5.42
7.09% 2.52%
90.7B
27.4B
-17.13% -16.65%
15.44
3.31
0.94% 76.21%
14.6B
15.8B
15.02% 26.90%
-26.19
0.92
6.17% 77.01%
MID-CAP
4.8B
1.7B
14.11% 18.79%
13.58
2.9
49.61% 324.78%
4.3B
4.7B
-2.94% -9.06%
-1.1K
0.93
5.74% 96.18%
3.1B
8.8B
-0.23% 18.85%
-5.25
0.35
7.79% -163.11%
2.5B
601.3M
-0.28% 70.16%
18.38
4.14
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.9
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
20.7M
84.1M
58.23% -28.98%
-0.97
0.22
2882.68% -145.15%
16.8M
111.1M
-6.33% -18.68%
-1.05
0.15
-10.43% 84.90%
2.4M
20.0M
-35.83% -91.10%
-0.17
0.12
137.71% 66.04%

Avadel Pharmaceuticals PLC News

Latest updates
Simply Wall St13 Feb 202412:09 pm
Quartz3 months ago

Avadel Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue368.9%7,014,0001,496,000193,000320,500448,000192,000502,000812,000489,000432,000216,000--10,091,00012,243,00010,995,00014,229,00017,554,00016,437,00020,920,00019,826,000
Gross Profit372.4%6,897,0001,460,000-------------------
Costs and Expenses-17.6%42,007,00051,001,00028,298,00023,038,00016,960,00029,937,00028,626,00023,136,00025,663,00021,936,00014,811,00014,260,00013,697,000-30,178,00018,740,00018,342,00018,376,00022,005,00024,604,00096,341,00033,921,000
  S&GA Expenses-16.3%39,158,00046,778,00024,468,00016,981,00014,096,00021,804,00021,635,00021,026,00021,283,00015,174,00011,012,0008,974,0008,423,0007,095,0007,913,0007,663,0005,316,0006,758,00010,446,00023,200,00024,829,000
  R&D Expenses-32.5%2,849,0004,223,0003,830,0006,235,0002,933,0004,541,0006,991,0002,110,0004,380,0006,762,0003,852,0005,286,0005,569,0004,057,0005,530,0007,757,0007,539,00010,292,0007,329,0006,086,00011,402,000
EBITDA Margin-13.6%-62.36-54.89-41.25-41.66-41.13-44.91-41.38-35.16-9.61-4.760.140.43---------
Interest Expenses-13.8%1,978,0002,295,0003,259,0003,255,0003,564,0003,506,0002,017,0004,154,0001,929,0001,930,0001,929,0003,308,0003,259,0003,237,0003,190,0003,190,0003,125,0003,106,0003,062,0003,045,0003,000,000
Income Taxes-1.1%89,00090,000-580,00085,00070,00030,193,000-4,323,000-4,343,000-5,101,000-3,765,000-2,607,000-2,852,000-5,040,0005,292,000-9,510,000-8,997,0002,234,0001,781,000-374,000-14,533,000-691,000
Earnings Before Taxes43.8%-36,185,000-64,342,000-31,364,000-27,365,000-20,076,000-33,251,000-30,747,000-26,644,000-27,103,000-23,346,000-16,052,000-14,130,000-16,743,00036,166,000-10,375,000-11,736,000-6,630,000-6,824,000-13,392,000-78,392,000-16,462,000
EBT Margin-11.3%-67.97-61.10-47.83-47.56-47.25-50.25-46.03-39.75-10.98-5.70-0.62-0.23---------
Net Income43.7%-36,274,000-64,432,000-30,784,000-27,450,000-20,146,000-63,444,000-26,424,000-22,301,000-22,002,000-19,581,000-13,445,000-11,278,000-11,703,00030,874,000-865,000-2,739,000-8,864,000-8,605,000-13,018,000-63,859,000-15,771,000
Net Income Margin-11.3%-67.84-60.95-60.53-58.67-56.47-57.26-38.54-33.00-9.03-4.54-0.320.31---------
Free Cashflow-19.4%-38,226,000-32,023,000-30,233,000-15,366,000-7,519,000-14,090,000-34,045,000-22,506,000-21,238,000-10,153,000-23,439,000-19,190,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets1.1%203201141133146158221247264283293312328341208151156166174190269
  Current Assets0.6%17217110910111312616119220623124226328227713182.0089.0097.00102125148
    Cash Equivalents3.7%52.0050.0083.0074.0061.0054.0061.0051.0058.0067.0059.0072.0083.0010274.0010.0013.0017.0010.009.0018.00
  Inventory267.3%5.001.00------------4.004.002.003.004.005.006.00
  Net PPE-9.4%1.001.001.001.001.000.000.000.000.000.000.000.000.000.000.001.001.001.002.002.002.00
  Goodwill0%17.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0017.0018.0018.0018.0018.0018.0018.0018.00
Liabilities60.9%93.0058.00179154158161166169165164156149156159176181183183183188203
  Current Liabilities5.0%54.0052.0079.0056.0042.0046.0044.0021.0018.0016.009.0015.0023.0027.0032.0036.0032.0034.0031.0038.0047.00
  Long Term Debt---93.0092.00110108117142142142141128127125123122120119117116114
    LT Debt, Current1.6%21.0021.0021.0038.0026.0026.0026.00---------0.000.000.000.000.00
    LT Debt, Non Current---93.0092.00110108117142142142141128127125123122120119117116114
Shareholder's Equity-23.1%11014360359057356055.0078.0099.0011913716217118232.004344344344343.0066.00
  Retained Earnings-5.3%-716-680-616-585-557-537-474-447-425-403-383-384-372-361-392-391-388-379-371-357-294
  Additional Paid-In Capital0.4%852849603590573560554549547544542567565615497434434434434434433
Shares Outstanding0.1%89.0089.0064.0063.0059.0059.0059.0059.0059.0058.0058.0058.00---------
Float------142---390---467---98.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-19.4%-38,226-32,023-30,233-15,366-6,803-14,090-34,045-22,506-21,238-10,153-23,413-19,125-10,192-7,781-11,636-8,253-7,419-1,447-21,206-24,526-20,248
  Share Based Compensation-59.1%3,1277,6441,5221,9271,9236582,5052,7842,3592,0011,7281,294194769742342-22955.003516622,832
Cashflow From Investing110.6%9,821-92,9085,06622,8752,52412,04842,25115,32012,29418,12411,1917,241-9,300-80,88813,2265,1703,2178,94621,39016,20726,024
Cashflow From Financing-66.7%30,46091,54434,4426,62210,715-4,8032,009-114-149183-16.00117,30662,210-41.00-41.00-37.0092.00-76.00-425
  Buy Backs----------------------

AVDL Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]    
Net loss$ (36,274)$ (20,146)$ (131,490)$ (110,014)
Other comprehensive (loss) income, net of tax:    
Foreign currency translation loss(303)(647)(120)(1,489)
Net other comprehensive income (loss), net of income tax expense of $0, $0, $0 and $0, respectively295(934)511(2,480)
Total other comprehensive (loss) income, net of tax(8)(1,581)391(3,969)
Total comprehensive loss$ (36,282)$ (21,727)$ (131,099)$ (113,983)

AVDL Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 51,811,000$ 73,981,000
Marketable securities101,368,00022,518,000
Accounts receivable, net6,239,0000
Inventories5,286,0000
Research and development tax credit receivable1,199,0002,248,000
Prepaid expenses and other current assets6,352,0002,096,000
Total current assets172,255,000100,843,000
Property and equipment, net648,000839,000
Operating lease right-of-use assets2,804,0001,713,000
Goodwill16,836,00016,836,000
Research and development tax credit receivable409,0001,232,000
Other non-current assets10,148,00011,322,000
Total assets203,100,000132,785,000
Current liabilities:  
Current portion of long-term debt21,187,00037,668,000
Current portion of operating lease liability916,000960,000
Accounts payable13,263,0007,890,000
Accrued expenses17,957,0007,334,000
Other current liabilities731,0001,941,000
Total current liabilities54,054,00055,793,000
Long-term debt091,614,000
Long-term operating lease liability1,928,000780,000
Royalty financing obligation31,151,0000
Other non-current liabilities5,818,0005,743,000
Total liabilities92,951,000153,930,000
Shareholders’ equity (deficit):  
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; 5,194 issued and outstanding at September 30, 2023 and 488 issued and outstanding at December 31, 202252,0005,000
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 89,398 issued and outstanding at September 30, 2023 and 62,878 issued and outstanding at December 31, 2022893,000628,000
Additional paid-in capital851,865,000589,783,000
Accumulated deficit(716,710,000)(585,220,000)
Accumulated other comprehensive loss(25,951,000)(26,341,000)
Total shareholders’ equity (deficit)110,149,000(21,145,000)
Total liabilities and shareholders’ equity (deficit)$ 203,100,000$ 132,785,000
AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEwww.avadel.com
 EMPLOYEES41

Avadel Pharmaceuticals PLC Frequently Asked Questions


What is the ticker symbol for Avadel Pharmaceuticals PLC? What does AVDL stand for in stocks?

AVDL is the stock ticker symbol of Avadel Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avadel Pharmaceuticals PLC (AVDL)?

As of Thu Feb 22 2024, market cap of Avadel Pharmaceuticals PLC is 1.13 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers.

What is the fair value of AVDL stock?

You can check AVDL's fair value in chart for subscribers. The fair value of Avadel Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avadel Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVDL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avadel Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether AVDL is over valued or under valued. Whether Avadel Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Avadel Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVDL.

What is Avadel Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AVDL's PE ratio (Price to Earnings) is -7.12 and Price to Sales (PS) ratio is 541.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVDL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avadel Pharmaceuticals PLC's stock?

In the past 10 years, Avadel Pharmaceuticals PLC has provided 0.028 (multiply by 100 for percentage) rate of return.